Ascentage Pharma Group International (NASDAQ:AAPG) Sees Strong Trading Volume – Should You Buy?

Shares of Ascentage Pharma Group International – Unsponsored ADR (NASDAQ:AAPG) saw strong trading volume on Tuesday . 7,701 shares were traded during mid-day trading, an increase of 143% from the previous session’s volume of 3,172 shares.The stock last traded at $21.2950 and had previously closed at $21.50.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently weighed in on the company. Deutsche Bank Aktiengesellschaft assumed coverage on Ascentage Pharma Group International in a research note on Friday, April 24th. They issued a “buy” rating and a $40.00 price objective for the company. BTIG Research reissued a “buy” rating and set a $48.00 price target on shares of Ascentage Pharma Group International in a research note on Monday, April 13th. Finally, China Intl Cap upgraded Ascentage Pharma Group International to a “strong-buy” rating in a research report on Monday, April 6th. Two equities research analysts have rated the stock with a Strong Buy rating and six have issued a Buy rating to the stock. According to MarketBeat, Ascentage Pharma Group International has an average rating of “Buy” and a consensus target price of $46.67.

Ascentage Pharma Group International Trading Down 5.5%

The company has a quick ratio of 1.77, a current ratio of 1.79 and a debt-to-equity ratio of 0.57. The firm has a fifty day moving average price of $23.88 and a two-hundred day moving average price of $26.74.

Ascentage Pharma Group International (NASDAQ:AAPG) last issued its quarterly earnings results on Wednesday, March 25th. The company reported ($0.52) earnings per share for the quarter. The firm had revenue of $24.72 million during the quarter. On average, equities research analysts anticipate that Ascentage Pharma Group International – Unsponsored ADR will post -1.09 earnings per share for the current year.

Institutional Investors Weigh In On Ascentage Pharma Group International

Several hedge funds and other institutional investors have recently modified their holdings of the business. Citadel Advisors LLC purchased a new stake in shares of Ascentage Pharma Group International in the third quarter worth approximately $383,000. XY Capital Ltd grew its stake in Ascentage Pharma Group International by 224.2% in the third quarter. XY Capital Ltd now owns 18,120 shares of the company’s stock worth $707,000 after purchasing an additional 12,530 shares in the last quarter. UBS Group AG grew its stake in Ascentage Pharma Group International by 149.4% in the third quarter. UBS Group AG now owns 18,345 shares of the company’s stock worth $716,000 after purchasing an additional 10,988 shares in the last quarter. ABC Arbitrage SA bought a new position in Ascentage Pharma Group International in the third quarter worth approximately $204,000. Finally, Mirae Asset Global Investments Co. Ltd. bought a new position in Ascentage Pharma Group International in the third quarter worth approximately $96,000.

Ascentage Pharma Group International Company Profile

Ascentage Pharma Group International is a clinical‐stage biopharmaceutical company focused on developing small‐molecule therapeutics that modulate programmed cell death pathways, including the Bcl‐2 family and the MDM2–p53 axis. Its pipeline features orally bioavailable inhibitors such as APG-2575, a selective Bcl-2 inhibitor, and APG-115, a potent MDM2 antagonist, both aimed at reactivating apoptosis in cancer cells across hematologic malignancies and solid tumors.

Founded in 2008 by biotechnology entrepreneur Dr.